US3819820A - Irradiated substance and compound and method of preparing the same - Google Patents
Irradiated substance and compound and method of preparing the same Download PDFInfo
- Publication number
- US3819820A US3819820A US00859141A US85914169A US3819820A US 3819820 A US3819820 A US 3819820A US 00859141 A US00859141 A US 00859141A US 85914169 A US85914169 A US 85914169A US 3819820 A US3819820 A US 3819820A
- Authority
- US
- United States
- Prior art keywords
- irradiated
- concentration
- silver
- substance
- same
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000126 substance Substances 0.000 title abstract description 26
- 150000001875 compounds Chemical class 0.000 title abstract description 21
- 238000000034 method Methods 0.000 title description 14
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 21
- 229910001385 heavy metal Inorganic materials 0.000 abstract description 14
- 229910052723 transition metal Inorganic materials 0.000 abstract description 7
- 150000003624 transition metals Chemical class 0.000 abstract description 7
- 239000003899 bactericide agent Substances 0.000 abstract description 6
- 231100000344 non-irritating Toxicity 0.000 abstract description 4
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 18
- 229910052709 silver Inorganic materials 0.000 description 18
- 229910052751 metal Inorganic materials 0.000 description 16
- 239000002184 metal Substances 0.000 description 16
- 239000002245 particle Substances 0.000 description 16
- 239000004332 silver Substances 0.000 description 16
- 239000000243 solution Substances 0.000 description 14
- 239000013522 chelant Substances 0.000 description 9
- 229910052802 copper Inorganic materials 0.000 description 9
- 239000010949 copper Substances 0.000 description 9
- QMGVPVSNSZLJIA-FVWCLLPLSA-N strychnine Chemical compound O([C@H]1CC(N([C@H]2[C@H]1[C@H]1C3)C=4C5=CC=CC=4)=O)CC=C1CN1[C@@H]3[C@]25CC1 QMGVPVSNSZLJIA-FVWCLLPLSA-N 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 230000008569 process Effects 0.000 description 8
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 229910052737 gold Inorganic materials 0.000 description 7
- 239000010931 gold Substances 0.000 description 7
- 230000035876 healing Effects 0.000 description 7
- 230000005855 radiation Effects 0.000 description 7
- 229910052702 rhenium Inorganic materials 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 6
- QMGVPVSNSZLJIA-UHFFFAOYSA-N Nux Vomica Natural products C1C2C3C4N(C=5C6=CC=CC=5)C(=O)CC3OCC=C2CN2C1C46CC2 QMGVPVSNSZLJIA-UHFFFAOYSA-N 0.000 description 6
- RRKTZKIUPZVBMF-IBTVXLQLSA-N brucine Chemical compound O([C@@H]1[C@H]([C@H]2C3)[C@@H]4N(C(C1)=O)C=1C=C(C(=CC=11)OC)OC)CC=C2CN2[C@@H]3[C@]41CC2 RRKTZKIUPZVBMF-IBTVXLQLSA-N 0.000 description 6
- 231100000252 nontoxic Toxicity 0.000 description 6
- 230000003000 nontoxic effect Effects 0.000 description 6
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 6
- 241000191967 Staphylococcus aureus Species 0.000 description 5
- RRKTZKIUPZVBMF-UHFFFAOYSA-N brucine Natural products C1=2C=C(OC)C(OC)=CC=2N(C(C2)=O)C3C(C4C5)C2OCC=C4CN2C5C31CC2 RRKTZKIUPZVBMF-UHFFFAOYSA-N 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 5
- WUAPFZMCVAUBPE-UHFFFAOYSA-N rhenium atom Chemical compound [Re] WUAPFZMCVAUBPE-UHFFFAOYSA-N 0.000 description 5
- 241001279009 Strychnos toxifera Species 0.000 description 4
- 230000032683 aging Effects 0.000 description 4
- 229910052741 iridium Inorganic materials 0.000 description 4
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 4
- 150000002739 metals Chemical class 0.000 description 4
- 229910052697 platinum Inorganic materials 0.000 description 4
- BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 4
- 229960005453 strychnine Drugs 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 239000003440 toxic substance Substances 0.000 description 4
- 229910052684 Cerium Inorganic materials 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 229910052777 Praseodymium Inorganic materials 0.000 description 3
- 229910052774 Proactinium Inorganic materials 0.000 description 3
- 229910052771 Terbium Inorganic materials 0.000 description 3
- 229910052776 Thorium Inorganic materials 0.000 description 3
- 229910052770 Uranium Inorganic materials 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 229910052793 cadmium Inorganic materials 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 229910052735 hafnium Inorganic materials 0.000 description 3
- 230000001678 irradiating effect Effects 0.000 description 3
- 229910052748 manganese Inorganic materials 0.000 description 3
- 239000011572 manganese Substances 0.000 description 3
- 229910052750 molybdenum Inorganic materials 0.000 description 3
- 229910000510 noble metal Inorganic materials 0.000 description 3
- 229910052762 osmium Inorganic materials 0.000 description 3
- 229910052763 palladium Inorganic materials 0.000 description 3
- 229910052703 rhodium Inorganic materials 0.000 description 3
- 229910052707 ruthenium Inorganic materials 0.000 description 3
- 229910052721 tungsten Inorganic materials 0.000 description 3
- 229910052720 vanadium Inorganic materials 0.000 description 3
- 229910052725 zinc Inorganic materials 0.000 description 3
- 229910052726 zirconium Inorganic materials 0.000 description 3
- 235000014469 Bacillus subtilis Nutrition 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 241000191963 Staphylococcus epidermidis Species 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000000711 cancerogenic effect Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 230000006003 cornification Effects 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229910052753 mercury Inorganic materials 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 150000002978 peroxides Chemical class 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000010948 rhodium Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229910052719 titanium Inorganic materials 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241001067541 Lorma Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 1
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- 206010039792 Seborrhoea Diseases 0.000 description 1
- FOIXSVOLVBLSDH-UHFFFAOYSA-N Silver ion Chemical compound [Ag+] FOIXSVOLVBLSDH-UHFFFAOYSA-N 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 206010040954 Skin wrinkling Diseases 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 150000001721 carbon Chemical class 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229930016876 colchicine alkaloid Natural products 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 201000003740 cowpox Diseases 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 230000005670 electromagnetic radiation Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- ACGUYXCXAPNIKK-UHFFFAOYSA-N hexachlorophene Chemical compound OC1=C(Cl)C=C(Cl)C(Cl)=C1CC1=C(O)C(Cl)=CC(Cl)=C1Cl ACGUYXCXAPNIKK-UHFFFAOYSA-N 0.000 description 1
- 229960004068 hexachlorophene Drugs 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 206010021198 ichthyosis Diseases 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- GKOZUEZYRPOHIO-UHFFFAOYSA-N iridium atom Chemical compound [Ir] GKOZUEZYRPOHIO-UHFFFAOYSA-N 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000004533 oil dispersion Substances 0.000 description 1
- 239000012053 oil suspension Substances 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 231100000683 possible toxicity Toxicity 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 229960003147 reserpine Drugs 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 208000008742 seborrheic dermatitis Diseases 0.000 description 1
- 239000010944 silver (metal) Substances 0.000 description 1
- 229940100890 silver compound Drugs 0.000 description 1
- 150000003379 silver compounds Chemical class 0.000 description 1
- -1 silver ions Chemical class 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- AGGKEGLBGGJEBZ-UHFFFAOYSA-N tetramethylenedisulfotetramine Chemical compound C1N(S2(=O)=O)CN3S(=O)(=O)N1CN2C3 AGGKEGLBGGJEBZ-UHFFFAOYSA-N 0.000 description 1
- 229910052716 thallium Inorganic materials 0.000 description 1
- BKVIYDNLLOSFOA-UHFFFAOYSA-N thallium Chemical compound [Tl] BKVIYDNLLOSFOA-UHFFFAOYSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229910001428 transition metal ion Inorganic materials 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/242—Gold; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/10—Inactivation or decontamination of a medicinal preparation prior to administration to an animal or a person
- A61K41/17—Inactivation or decontamination of a medicinal preparation prior to administration to an animal or a person by ultraviolet [UV] or infrared [IR] light, X-rays or gamma rays
Definitions
- the present invention relates to radioactivated substances and compounds and methods of preparing the same, being more particularly directed to bacteriaand virus-killing and irritation-healing compounds; the term radioactivated being used to mean irradiation or electrically exciting or charging by ultraviolet, gamma rays, X-rays, beta particles, neutrons, protons, deuterons and the like, all having quantum energy at least as high as ultraviolet, but not long wavelength electromagnetic waves, and with the irradiated substances and compounds of the invention, however, having no detectable residual radioactivity.
- This application is a continuation-in-part of U.S. application Ser. No. 749,141, filed July 3l, 1968, now abandoned.
- a small critical concentration of irradiated colloidal particulate heavy metals can accomplish remarkable bactericidal, irritation-dissipating and similar curative functions in such low concentrations as to itself be nonirritating, and, unlike X-rays, free of radioactivity and otherwise harmless of tissue and the like.
- An object of the invention accordingly, is to provide a new and improved irradiated substance and/or compound and method or process of preparing and using the same that shall attain the above and other advantages.
- a further object is to provide novel substances and/r compounds of more general utility, as well.
- FIG. l of which is an experimentally obtained graph illustrating the critical concentration discovery underlying the preferred form of the invention.
- FIG. 2 is a similar graph showing the relative kill efcacy upon Staphylococcus aureus, Escherichia coli and b. subtilis of a number of heavy and transition metals exhibiting the phenomenon underlying such discovery.
- That discovery includes the finding that very small critical concentrations of colloidal particulate heavy and transition metals, such as the noble metals of Ag, Au, Pt, Pd, Rh, Ru and Cu, Cd, Re, Ti, Zr, Mo, Mn, Os, Ir, Tb, Pr, Ce, Th, Pa, U, Hf, W, V, Zn, Hg (and to rather minor extents Fe and Co)-all hereinafter generically referred to as the heavy and transition metals-when appropriately radioactivated or irradiated as above-described, can produce the novel results before summarized; while lesser 0r greater concentrations do not function to achieve such results.
- colloidal particulate heavy and transition metals such as the noble metals of Ag, Au, Pt, Pd, Rh, Ru and Cu, Cd, Re, Ti, Zr, Mo, Mn, Os, Ir, Tb, Pr, Ce, Th, Pa, U, Hf, W, V, Zn, Hg (and to rather minor extents Fe and Co
- ultraviolet, and electric field generators of, for example, gamma and X-rays have been found to be effective radioactivators or irradiators for the purposes of the invention; while heat and electromagnetic radiation of longer wavelength than ultraviolet rays were not found to be effective.
- a colloidal silver suspension in a non-reactive water carrier solution in which the particulate silver concentration is limited rather critically to the order of about 1.5 103 grams per cubic centimeter (or about 0.15% by weight) and the silver is irradiated as by a source of gamma radiation, has been found to provide remarkable bactericidal properties despite the minuscule quantity of the silver.
- the speed of reaction on Staphylococcus aureus bacteria is plotted along the ordinate in units of colonies destroyed per minute, as a function of concentration of the silver ion, plotted in units of 10*3 grams per cubic centimeter along the abscissa. From this experimentally obtained data, it is evident that the beforementioned concentration of the order of about 1.5)(10*a grams per cubic centimeter is a rather critical and highly unexpected optimum concentration; lower concentrations, such as one-third the same, being rather inetcacious, as are higher concentrations, such as twice as much or greater.
- said solution produced a 50% kill of Staphylococcus albus in 7 minutes; and a 95 kill in about 9 minutes.
- this minuscule colloidal particulate irradiated silver concentration is entirely harmless and non-irritating to the skin and free of radioactivity; and yet is comparable in its bactericidal properties to, for example, the widely used m-cresol, which, to the contrary, must be used in such strong concentration to be effective, that it is ⁇ decidedly irritating to the user, and, indeed, precautions must be taken to prevent prolonged skin contact with the same.
- the irradiation source if of gamma rays or the like, need not exceed substantially 1.3 microcun'es to produce the desired ecacious product.
- a silver chelate, formed with the alkaloids of the strychnine family (strychnine, brucine and reserpine) in a non-toxic, non-reactive carrier has Staphylococcus Staphylococcus aureus albus 50% kill... 3.5 'minute 6.2 minutes. 95% kill 5.5 minutes 8.4 minutes.
- radio-activated colloidal heavy metal i.e. the silver, copper, gold or rhenium or other similar heavy or transition-type metal before listed, for example
- SDA 401 ethanol denatured with brucine
- inert mineral oil inert mineral oil
- boraxemulsified water solution inert mineral oil
- each of, for example, irradiated copper, gold, platinum, iridium, manganese, and rhenium, ⁇ colloidal particles of the same size range have been proven effective as bactericides, producing kills of the same bacteria above-listed. Theoretically this would appear to apply to all heavy and transition-type metals, so prepared, though the efficacy will vary with the element. Substantially the same approximately 1.5 10-3 grams per cubic centimeter low-concentration optimum constant of the silver particles, for example, was found to exist for gold, rhenium and copper colloidal particles, with gold being much more efiicacious in time of kill, as indicated in FIG. 2. In the tests shown in FIG.
- rhenium proved more efficacious than silver, and copper showed a remarkable efficacy for greater concentrations beyond the low-concentration optimum.
- Other tested irradiated metals that also show this same substantially 1.5 1(l3 grams/cc. constant include the before-listed Ti, Zr, Mo, Mn, Ru, Rh, Pd, Os, Ir, Pt, Tb, Pr, Ce, Th, Pa, U, Hf, W, V, Zn, Cd and Hg.
- ultraviolet-irradiated inorganic chelate compounds including sunlight-irradiated
- particulated heavy and transition metal ions found to be bactericidal in water solution of the above-mentioned concentration
- alkaloidal solutions containing brucine, strychnine and colchicine alkaloids
- trace metals of copper and thallium These proved to be effective against each of Escherichia coil, Staphylococcus aureus and Bacillus subtils.
- the transition metals abovelisted can have a coordination or valence number 4, capable of electron transitions or resonances between the second and third electron orbits. This may account for the apparently universal 1.5 X3 constant previously discussed--the bacteria, all being of substantially the same range of dimensions, perhaps being electromechanically destroyed by such oscillations.
- the optimum concentration effect shown in the drawing is obviously highly desirable from' coniderations of economy and possible toxicity, it does prevent continued efficacy upon substantial dilution of the solution.
- the solutions may be substantially more concentrated or saturated, as shown to the far right in FIG. 2. (and beyond), though the bactericidal and healing effects do not, except in the case of the particular copper tests indicated, appear to exceed those attainable with the minimal optimum concentration (and in many cases, do not reach the same peak of performance). To permit such dilution to the order of lm), without dropping the efficacy more than about 12%,
- a practical use concentration may be centered about 8.3% (by weight) with about 10-15% seemingly a useful commercial or economic (diminishing marginal return) limit.
- irradiated chelates which do not appear to produce these results in the absence of irradiation
- tetramine copper-2, bis-ethylene diamine gold-Z, hexacyanomanganate and hexachloro rheniate all of which have excellent bactericidal properties at this 4% concentration and above.
- a process for preparing a non-toxic substance for bactericdal and treating purposes that comprises combining at least one of the heavy and transition metals, including the noble metals, with a carrier non-reactive to the metal, the metals being selected from the group consisting of Ag, 'Au, Pt, Pd, Rh, Cu, Ru, Os, Ir, Tb, Pr, Ce, natural Th, Pa, natural U, Hf, W, V, Re, Zn, Cd, Hg, Ti, Zr, Mo, and Mn, irradiating said metal with radiation having quantum energy at least as high as ultraviolet, maintaining the metal in colloidal particulate form and largely unclustered, and limiting the particle concentration to a range of from about hundredths to about tenths of a percent, by weight.
- a process for preparing a non-toxic substance for bactericidal and curing purposes that comprises combining platinum metal with a carrier non-reactive to the metal, irradiating said metal with radiation having quantum energy at least as high as ultraviolet, maintaining the metal in colloidal particulate form and largely unclustered, and limiting the particle concentration to a range from about 7 8 hundredths to about tenths of a percent, by weight, the 3,172,817 3/ 1965 Leupold etal 424--287 X particles comprising said metal at least in part dissociated 2,329,147 9/ 1943 Troch et al 424-1 X from a chelate thereof.
- a non-toxic substance for bactericidal and treating BENJAMIN R- PADGETF, Pflmafy Examiner purposes produced by the process of claim 13.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
BACTERICIDE AND A CELL AND TISSUE HEALER, NON-IRRITATING TO THE USER.
THIS DISCCLOSURE DEALS WITH NOVEL IRRADIATED SUBSTANCES AND COMPOUNDS PREFERABLY CONTAINING A RATHER CRITICAL CONCENTRATION OF COLLOIDAL PARTICULATE HEAVY METALS INCLUDING THE NOBLE HEAVY AND TRANSITION METALS, AND HAVING AMONG OTHER ADVANTAGEOUS USES, UNUSUAL EFFICACY AS A
THIS DISCCLOSURE DEALS WITH NOVEL IRRADIATED SUBSTANCES AND COMPOUNDS PREFERABLY CONTAINING A RATHER CRITICAL CONCENTRATION OF COLLOIDAL PARTICULATE HEAVY METALS INCLUDING THE NOBLE HEAVY AND TRANSITION METALS, AND HAVING AMONG OTHER ADVANTAGEOUS USES, UNUSUAL EFFICACY AS A
Description
June 25, 1974 J. L oRlNA ETAL 3,819,820 IRRADIATED SUBSTANCE AND COIPOUND' AND METHOD 0F PREPARING THE SAME Filed Sept. 18. 1969 SPEED or: REACHON 0N sTAPHuococcus AUREus (No. oF coLomEs DE sTRoYeo PER MIN 5 RATE E F H CACI IOW-'AG AS STND. Il, f /f Alg ma INVENTORS JOHN LoRmA f f Gr. RoNALv ALulsY ,f NORMAN D.\ ouo l* k f l ROBERT H. RmEs coNcENTTwN (PERCENT) ATTORNEYS 3,819,820 IRRADIATED SUBSTANCE AND COMPOUND AND METHOD OF PREPARING THE SAME John Lorina, 30 Pond St., Hull, Mass. 02045; G. Ronald Aluisy, 699 Bridge St., North Weymouth, Mass. 02169; Norman D. Loud, 39 Academy Ave., East Weymouth, Mass. 02169; and Robert H. Rines, 25 Shady Brook Lane, Belmont, Mass. 02178 Continuation-impart of abandoned application Ser. No. 749,141, July 3l, 1968. This application Sept. 18, 1969, Ser. No. 859,141
Int. Cl. A61k 27/04 U.S. Cl. 424--1 14 Claims ABSTRACT OF THE DISCLOSURE This disclosure deals with novel irradiated substances and compounds preferably containing a rather critical concentration of colloidal particulate heavy metals including the noble heavy and transition metals, and having among other advantageous uses, unusual efficacy as a bactericide and a cell and tissue healer, non-irritating to the user.
The present invention relates to radioactivated substances and compounds and methods of preparing the same, being more particularly directed to bacteriaand virus-killing and irritation-healing compounds; the term radioactivated being used to mean irradiation or electrically exciting or charging by ultraviolet, gamma rays, X-rays, beta particles, neutrons, protons, deuterons and the like, all having quantum energy at least as high as ultraviolet, but not long wavelength electromagnetic waves, and with the irradiated substances and compounds of the invention, however, having no detectable residual radioactivity. This application is a continuation-in-part of U.S. application Ser. No. 749,141, filed July 3l, 1968, now abandoned.
While the art is replete with bactericides and diseasecuring compounds of a wide variety of types, they all have limitations and disadvantages that restrict their safe or eicacious usage. As an illustration, m-cresol bactericide, widely used in hospitals and the like for clean rooms and to prevent contamination, requires a sufficiently strong concentration to b'e effective that it becomes irritating to the skin. Rather large doses of X-ray and other radiation have also been employed for bacteria and virus killing and cancer and other disease-treatment or -curing purposes; but again such treatment is attendant upon disadvantages, including high radiation damage.
As explained in said application, underlying the present invention, in summary, is the discovery that, in preferred form, a small critical concentration of irradiated colloidal particulate heavy metals, appropriately combined in a suitable carrier, can accomplish remarkable bactericidal, irritation-dissipating and similar curative functions in such low concentrations as to itself be nonirritating, and, unlike X-rays, free of radioactivity and otherwise harmless of tissue and the like.
An object of the invention, accordingly, is to provide a new and improved irradiated substance and/or compound and method or process of preparing and using the same that shall attain the above and other advantages.
Other objects are to provide novel noble heavy and transition metal chelates of bactericidal and medicinal efficacy.
A further object is to provide novel substances and/r compounds of more general utility, as well.
Other and further objects will be hereinafter set forth and are more particularly delineated in the appended claims.
The invention will now be described with reference to United States Patent() fil the accompanying drawing, FIG. l of which is an experimentally obtained graph illustrating the critical concentration discovery underlying the preferred form of the invention; and
FIG. 2 is a similar graph showing the relative kill efcacy upon Staphylococcus aureus, Escherichia coli and b. subtilis of a number of heavy and transition metals exhibiting the phenomenon underlying such discovery.
That discovery includes the finding that very small critical concentrations of colloidal particulate heavy and transition metals, such as the noble metals of Ag, Au, Pt, Pd, Rh, Ru and Cu, Cd, Re, Ti, Zr, Mo, Mn, Os, Ir, Tb, Pr, Ce, Th, Pa, U, Hf, W, V, Zn, Hg (and to rather minor extents Fe and Co)-all hereinafter generically referred to as the heavy and transition metals-when appropriately radioactivated or irradiated as above-described, can produce the novel results before summarized; while lesser 0r greater concentrations do not function to achieve such results. As before stated, ultraviolet, and electric field generators of, for example, gamma and X-rays, have been found to be effective radioactivators or irradiators for the purposes of the invention; while heat and electromagnetic radiation of longer wavelength than ultraviolet rays were not found to be effective.
As a trst example, a colloidal silver suspension in a non-reactive water carrier solution, in which the particulate silver concentration is limited rather critically to the order of about 1.5 103 grams per cubic centimeter (or about 0.15% by weight) and the silver is irradiated as by a source of gamma radiation, has been found to provide remarkable bactericidal properties despite the minuscule quantity of the silver.
yReferring to FIG. 1, the speed of reaction on Staphylococcus aureus bacteria is plotted along the ordinate in units of colonies destroyed per minute, as a function of concentration of the silver ion, plotted in units of 10*3 grams per cubic centimeter along the abscissa. From this experimentally obtained data, it is evident that the beforementioned concentration of the order of about 1.5)(10*a grams per cubic centimeter is a rather critical and highly unexpected optimum concentration; lower concentrations, such as one-third the same, being rather inetcacious, as are higher concentrations, such as twice as much or greater. This critical concentration-destruction ecacy, moreover, was found to coincide, also, with what might be termed the measured optimum ionization constant (which involves the amount of freely conductive silver ions and the maximum chemical activity or optimum conductivity in a distilled water solution).
Using the standard Frost Little Plate method, a 50% kill ofStaphylococcus aureus was obtained with the above solution in about 4 minutes; and a 95% kill in about 6 minutes.
As still another illustration with a different bacterium, said solution produced a 50% kill of Staphylococcus albus in 7 minutes; and a 95 kill in about 9 minutes.
It is to be observed, moreover, that this minuscule colloidal particulate irradiated silver concentration -is entirely harmless and non-irritating to the skin and free of radioactivity; and yet is comparable in its bactericidal properties to, for example, the widely used m-cresol, which, to the contrary, must be used in such strong concentration to be effective, that it is `decidedly irritating to the user, and, indeed, precautions must be taken to prevent prolonged skin contact with the same.
It has further been found that the irradiation source, if of gamma rays or the like, need not exceed substantially 1.3 microcun'es to produce the desired ecacious product.
As another example, a silver chelate, formed with the alkaloids of the strychnine family (strychnine, brucine and reserpine) in a non-toxic, non-reactive carrier has Staphylococcus Staphylococcus aureus albus 50% kill... 3.5 'minute 6.2 minutes. 95% kill 5.5 minutes 8.4 minutes.
As still a further illustration, with the said chelate coml kill of Staphylococcus albus in the same period, with bined about 140 parts per million in an inert, non-reactive v cornstarch-Water emulsion, similar bactericidal effects have been observed. In this chelate compound, the minute trace proportions of the strychnine and brucine alkaloids were about equal and about twice that of the reserpine alkaloid. In addition, the effective clearing up of acne and psoriasis has also been observed with this compound. Further, skin irritations (effected by needle stroking without leaving time for healing) that have been observed nor- `mally to developu skin cancer tumors sarcoma) on guinea pigs, when periodically covered by this compound (and despite continued needle stroking), progressively healed sufficiently that all indicia of the sarcoma disappeared. Other consistent healing effects have also been observed.
Additional non-toxic systemic and topical carriers, nonreactive with the said critical concentration of radio-activated colloidal heavy metal being used (i.e. the silver, copper, gold or rhenium or other similar heavy or transition-type metal before listed, for example), have also been thus successfully employed, including SDA 401 ethanol, denatured with brucine; inert mineral oil; and a boraxemulsified water solution.
An experimentally determined comparison between the particulated silver obtained from the silver chelate water solution (ultraviolet-irradiated and in the approximately l.5 l03 grams per cubic centimeter concentration) and a `6% solution of presently widely used hexachlorophene, showed the marked bactericidal superiority of the invention for several gram negative and positive bacteria, as follows:
' 100% kill in Vaboutl ten minutes. This is as compared with only relatively slight kills for the same silver colloidal particles, non-irradiated-which, though of some use in certain applications, is not nearly as efficacious as the irradiated particles.
Similarly, each of, for example, irradiated copper, gold, platinum, iridium, manganese, and rhenium,` colloidal particles of the same size range, have been proven effective as bactericides, producing kills of the same bacteria above-listed. Theoretically this would appear to apply to all heavy and transition-type metals, so prepared, though the efficacy will vary with the element. Substantially the same approximately 1.5 10-3 grams per cubic centimeter low-concentration optimum constant of the silver particles, for example, was found to exist for gold, rhenium and copper colloidal particles, with gold being much more efiicacious in time of kill, as indicated in FIG. 2. In the tests shown in FIG. l2, moreover, rhenium proved more efficacious than silver, and copper showed a remarkable efficacy for greater concentrations beyond the low-concentration optimum. Other tested irradiated metals that also show this same substantially 1.5 1(l3 grams/cc. constant include the before-listed Ti, Zr, Mo, Mn, Ru, Rh, Pd, Os, Ir, Pt, Tb, Pr, Ce, Th, Pa, U, Hf, W, V, Zn, Cd and Hg.
Other ultraviolet-irradiated inorganic chelate compounds (including sunlight-irradiated) with particulated heavy and transition metal ions found to be bactericidal in water solution of the above-mentioned concentration are alkaloidal solutions (containing brucine, strychnine and colchicine alkaloids) having trace metals of copper and thallium. These proved to be effective against each of Escherichia coil, Staphylococcus aureus and Bacillus subtils.
Among the healing effects, before-mentioned, is the unbelievably rapid reduction in burn histamine-type pain response, erythema and redness and absence of blister, all effected with both oil and water suspensions of each, for example, of the silver, gold, copper and, to a lesser extent, rhenium colloidal particulated compounds before tested as bactericides.
While it is sufficient to describe an invention in terms of the elements, compounds and results, it sometimes aids in understanding to theorize as the possible operation; though it is distinctly to be understood that the present invention is not dependent upon theories, whether accurate or inaccurate-it being sufficient to describe the invention as it has been found to work in practice and such The finely divided colloidal particles in the substances and compounds of the invention have been found to have a large number (in fact, in some measurements, or more, or an average number) of separate particles of size range between substantially 10-5 and 10-s cm., which are believed to be important to the cell penetration or other effects herein involved. Similarly dimensioned silver particles alone, not derived from chelates, but irradiated with X-rays (gamma), as before described, have also been found to produce substantial bactericidal and healing effects; to wit, such irradiated colloidal silver in water solution in the above-mentioned concentration produced-a that it may be practiced to produce the claimed results.
lIt appears likely, however, that the apparently universal nature of the bactericidal substances of the invention (no bacterium yet tried has not been rapidly killed) may reside in the supplying of appropriately small, unclustered and free heavy metal ions (probably freed by the irridiation or otherwise similarly electrically charged to prevent clustering) that, by induced electron exchange, effect a change (probably a reduction), either catalytically or by chemical combination, in the intracellular oxygen and peroxides generated at or in the vicinity of the cell. In the case of pathogenic organisms, this appears to debili- 93 of Staphylococcus aureus in five minutes, and a 91% 75 tate and destroy the same.
Evidence of further universality has been obtained in the efficacy of, for example, the silver compounds of the invention, against virus such as cow-pox and cold virus.
Concurrently, in the case of animal and human cells, this phenomenon also appears to control the metabolic rate through the oxygen and peroxide control or antioxidant activity or the like, possibly replacing such metal ions at the cells that may have been chemically combined or consumed by disease, radiation or other damage (or, in the case of prevention, that may subsequently be consumed, combined or rendered ineffective). It is an observable fact, however, that a type of healing and unusually rapid outward growth of light pink tissue occurs, void of the usual scabbing and inward slow-healing provided by nature, in diseased, cut and damaged tissue treated with substances of the invention, whether externally or systemically applied, act within the enzymic system to improve cellular efiiciency and healing. Differentiation in action upon strong and weak or diseased cells has been observed in the before-mentioned preliminary cancer studies; it being plausible that either replacement of unsubstituted carbon in benzene ring chains that are carcinogenic in the absence of such substitution, by the readily active freed or free-radical heavy metal ions in the compounds of the invention, or reconstituting of the metabolic oxygencontrol or similar process (or both), is an explanation for the observed phenomena. (See, for example, Chemical Basis of Carcinogenic Activity, G. M. Badger, 1962, p. 23.)
Apart from the noble metals, an interesting observation appears to be, moreover, that the transition metals abovelisted can have a coordination or valence number 4, capable of electron transitions or resonances between the second and third electron orbits. This may account for the apparently universal 1.5 X3 constant previously discussed--the bacteria, all being of substantially the same range of dimensions, perhaps being electromechanically destroyed by such oscillations.
These compounds of the present invention, moreover, have been preliminarily found to assist rather startingly in the slowing or inhibiting of certain processes associated with ageing; specifically, the continual application on a daily basis of an oil dispersion of particulated irradiated silver in the said optimum concentration, as before discussed, has been found to prevent cornification of the skin in cases of ichthyosis wherein a rapid localized ageing takes place as a result of the rapid cellular death rate involved in cornification of the skin.
Another element generally associated with the ageing process is the development of wrinkles accompanying the breakdown of the connective tissue layers of the skin, with resulting loss of elasticity. Such breakdown has been observed to become halted through similar application of the said compounds of the invention.
And still another example of a further element associated with the ageing process that has been found to become obviated through the application of the first-named water solution of the irradiated particulated silver (in the said optimum concentration), is non-infective seborrhea of the scalp involving an acceleration of cellular death rate. The use of such water solution has been found to result in the marked decrease in the index of cebrial activity.
While, moreover, the optimum concentration effect shown in the drawing is obviously highly desirable from' coniderations of economy and possible toxicity, it does prevent continued efficacy upon substantial dilution of the solution. For such purposes and others, accordingly, the solutions may be substantially more concentrated or saturated, as shown to the far right in FIG. 2. (and beyond), though the bactericidal and healing effects do not, except in the case of the particular copper tests indicated, appear to exceed those attainable with the minimal optimum concentration (and in many cases, do not reach the same peak of performance). To permit such dilution to the order of lm), without dropping the efficacy more than about 12%,
a practical use concentration may be centered about 8.3% (by weight) with about 10-15% seemingly a useful commercial or economic (diminishing marginal return) limit.
In the case of irradiated chelates, there lappear to be instances where the metal does not sufficiently dissociate therefrom to control the above effects as the colloidal particulated free metal, and where efficacy increases with concentration on a substantially continual basis. Chelates of coordination number 1 seem to fall within this category. For example, chelates of mercurous, cuprous, silver and aurous compounds have shown highly increased bactericidal kill effects (against Staphylococcus alureus, E. coli and B. subtilis) with about a 4% concentration. Included in these irradiated chelates (which do not appear to produce these results in the absence of irradiation) are tetramine copper-2, bis-ethylene diamine gold-Z, hexacyanomanganate and hexachloro rheniate, all of which have excellent bactericidal properties at this 4% concentration and above.
Further modifications will also occur to those skilled in this art, and all such are considered to fall within the spirit and scope of the invention as defined inthe appended claims. l
What is claimed is:
1. A process for preparing a non-toxic substance for bactericdal and treating purposes that comprises combining at least one of the heavy and transition metals, including the noble metals, with a carrier non-reactive to the metal, the metals being selected from the group consisting of Ag, 'Au, Pt, Pd, Rh, Cu, Ru, Os, Ir, Tb, Pr, Ce, natural Th, Pa, natural U, Hf, W, V, Re, Zn, Cd, Hg, Ti, Zr, Mo, and Mn, irradiating said metal with radiation having quantum energy at least as high as ultraviolet, maintaining the metal in colloidal particulate form and largely unclustered, and limiting the particle concentration to a range of from about hundredths to about tenths of a percent, by weight.
2. -A non-toxic substance for bactericidal and treating purposes produced by the process of claim 1.
3. A substance as claimed in claim 2 and in which the colloidal particles are in large proportion of the order from substantially 105 to 10-6 cm. in average size.
4. A substance as claimed in claim 2 and in which the particles comprise said metal at least in part dissociated from a chelate thereof.
5. A substance as claimed in claim 4 and in which said substance contains at least one of the family of strychnine alkaloids.
6. A substance as claimed in claim 5 and in which each of strychnine, brucine and reserpine alkaloids is present in said chelate.
7. `A substance as claimed in claim 6 and in which all of said alkaloids are present in content of the order of substantially 0.15 percent by weight.
`8. A substance as claimed in claim 7 and in which the proportions of said strychnine and brucine are approximately equal and yabout twice that of the reserpine alkaloid.
9. A substance as claimed in claim 4 and in which the chelate is of a heavy metal of coordination number 4.
:10. A substance as claimed in claim 2i and in which the particle concentration is of the order of substantially 1.5 103 grams per cubic centimeter.
I11. A substance as claimed in claim 2 and in which the particle concentration is substantially that at which the optimum chemical activity of the metal is attained.
12. A process as claimed in claim 1 and in which said irradiating step is carried out by producing radiation of the order of substantially 1.3 microcuries.
13. A process for preparing a non-toxic substance for bactericidal and curing purposes that comprises combining platinum metal with a carrier non-reactive to the metal, irradiating said metal with radiation having quantum energy at least as high as ultraviolet, maintaining the metal in colloidal particulate form and largely unclustered, and limiting the particle concentration to a range from about 7 8 hundredths to about tenths of a percent, by weight, the 3,172,817 3/ 1965 Leupold etal 424--287 X particles comprising said metal at least in part dissociated 2,329,147 9/ 1943 Troch et al 424-1 X from a chelate thereof.
14. A non-toxic substance for bactericidal and treating BENJAMIN R- PADGETF, Pflmafy Examiner purposes produced by the process of claim 13. 5 U S Cl X R References Cited 204-158 R, 158 HE; 424-132, 141, 145, 146, 262, 288, l UNITED STATES PATENTS 289 290 291 294 2,072,809v 3/1937 Bley 424-1 X 10
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US00859141A US3819820A (en) | 1968-07-31 | 1969-09-18 | Irradiated substance and compound and method of preparing the same |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US74914168A | 1968-07-31 | 1968-07-31 | |
| US00859141A US3819820A (en) | 1968-07-31 | 1969-09-18 | Irradiated substance and compound and method of preparing the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US3819820A true US3819820A (en) | 1974-06-25 |
Family
ID=27115064
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US00859141A Expired - Lifetime US3819820A (en) | 1968-07-31 | 1969-09-18 | Irradiated substance and compound and method of preparing the same |
Country Status (1)
| Country | Link |
|---|---|
| US (1) | US3819820A (en) |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2640510A1 (en) * | 1988-12-20 | 1990-06-22 | Therabion Sa Laboratoires | Activated trace elements, method for preparing them and compositions containing them which are useful for health |
| FR2660559A1 (en) * | 1990-04-05 | 1991-10-11 | Jacob Albert | Natural elements, with or without support, treated so that they can be used in medicine |
| US6274552B1 (en) | 1993-03-18 | 2001-08-14 | Cytimmune Sciences, Inc. | Composition and method for delivery of biologically-active factors |
| US6407218B1 (en) | 1997-11-10 | 2002-06-18 | Cytimmune Sciences, Inc. | Method and compositions for enhancing immune response and for the production of in vitro mabs |
| US20020192814A1 (en) * | 2001-04-30 | 2002-12-19 | Lawrence Tamarkin | Colloidal metal compositions and methods |
| US20040213760A1 (en) * | 1994-03-18 | 2004-10-28 | Lawrence Tamarkin | Composition and method for delivery of biologically-active factors |
| US20050175584A1 (en) * | 2004-01-28 | 2005-08-11 | Paciotti Giulio F. | Functionalized colloidal metal compositions and methods |
| US20090104114A1 (en) * | 2007-09-21 | 2009-04-23 | Cytimmune Sciences, Inc. | Nanotherapeutic Colloidal Metal Compositions and Methods |
| US20090148908A1 (en) * | 2007-11-08 | 2009-06-11 | Paciotti Giulio F | Compositions and methods for generating antibodies |
| US20100068261A1 (en) * | 2003-12-02 | 2010-03-18 | Cytimmune Sciences, Inc. | Methods and compositions for the production of monoclonal antibodies |
| US20110014118A1 (en) * | 2007-09-21 | 2011-01-20 | Lawrence Tamarkin | Nanotherapeutic colloidal metal compositions and methods |
-
1969
- 1969-09-18 US US00859141A patent/US3819820A/en not_active Expired - Lifetime
Cited By (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2640510A1 (en) * | 1988-12-20 | 1990-06-22 | Therabion Sa Laboratoires | Activated trace elements, method for preparing them and compositions containing them which are useful for health |
| FR2660559A1 (en) * | 1990-04-05 | 1991-10-11 | Jacob Albert | Natural elements, with or without support, treated so that they can be used in medicine |
| US6274552B1 (en) | 1993-03-18 | 2001-08-14 | Cytimmune Sciences, Inc. | Composition and method for delivery of biologically-active factors |
| US20040213760A1 (en) * | 1994-03-18 | 2004-10-28 | Lawrence Tamarkin | Composition and method for delivery of biologically-active factors |
| US8137989B2 (en) | 1994-03-18 | 2012-03-20 | Cytimmune Sciences, Inc. | Method for delivering a cytokine using a colloidal metal |
| US7387900B2 (en) | 1997-11-10 | 2008-06-17 | Cytimmune Sciences, Inc. | Colloidal metal compositions and methods |
| US7790167B2 (en) | 1997-11-10 | 2010-09-07 | Cyt Immune Sciences, Inc. | Methods and compositions for enhancing immune response and for the production of in vitro Mabs |
| US20030180252A1 (en) * | 1997-11-10 | 2003-09-25 | Lawrence Tamarkin | Methods and compositions for enhancing immune response and for the production of in vitro Mabs |
| US6528051B2 (en) | 1997-11-10 | 2003-03-04 | Cytimmune Sciences, Inc. | Methods and compositions for enhancing immune response |
| US20030053983A1 (en) * | 1997-11-10 | 2003-03-20 | Lawrence Tamarkin | Colloidal metal compositions and methods |
| US6407218B1 (en) | 1997-11-10 | 2002-06-18 | Cytimmune Sciences, Inc. | Method and compositions for enhancing immune response and for the production of in vitro mabs |
| US20070160572A1 (en) * | 1998-11-10 | 2007-07-12 | Lawrence Tamarkin | Colloidal metal compositions and methods |
| US7229841B2 (en) | 2001-04-30 | 2007-06-12 | Cytimmune Sciences, Inc. | Colloidal metal compositions and methods |
| US20020192814A1 (en) * | 2001-04-30 | 2002-12-19 | Lawrence Tamarkin | Colloidal metal compositions and methods |
| US8785202B2 (en) | 2001-04-30 | 2014-07-22 | Cytimmune Sciences, Inc. | Colloidal metal compositions and methods |
| USRE42524E1 (en) | 2001-04-30 | 2011-07-05 | Cytimmune Sciences, Inc. | Colloidal metal compositions and methods |
| US20100143298A1 (en) * | 2001-04-30 | 2010-06-10 | Lawrence Tamarkin | Colloidal metal compositions and methods |
| US20100068261A1 (en) * | 2003-12-02 | 2010-03-18 | Cytimmune Sciences, Inc. | Methods and compositions for the production of monoclonal antibodies |
| US7951614B2 (en) | 2003-12-02 | 2011-05-31 | Cytimmune Sciences, Inc. | Methods and compositions for the production of monoclonal antibodies |
| US20050175584A1 (en) * | 2004-01-28 | 2005-08-11 | Paciotti Giulio F. | Functionalized colloidal metal compositions and methods |
| US20110014118A1 (en) * | 2007-09-21 | 2011-01-20 | Lawrence Tamarkin | Nanotherapeutic colloidal metal compositions and methods |
| US20090104114A1 (en) * | 2007-09-21 | 2009-04-23 | Cytimmune Sciences, Inc. | Nanotherapeutic Colloidal Metal Compositions and Methods |
| US7960145B2 (en) | 2007-11-08 | 2011-06-14 | Cytimmune Sciences, Inc. | Compositions and methods for generating antibodies |
| US20090148908A1 (en) * | 2007-11-08 | 2009-06-11 | Paciotti Giulio F | Compositions and methods for generating antibodies |
| US8486663B2 (en) | 2007-11-08 | 2013-07-16 | Cytlmmune Sciences, Inc. | Compositions and methods for generating antibodies |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US3819820A (en) | Irradiated substance and compound and method of preparing the same | |
| Ren et al. | Photoresponsive materials for antibacterial applications | |
| CN110150316A (en) | A kind of preparation method of nano silver/subchloride composite bactericidal liquid | |
| US3856805A (en) | Silver zinc allantoin complex | |
| GB1270410A (en) | Colloidal composition and method of preparing the same | |
| Buettner et al. | Superoxide, hydrogen peroxide and singlet oxygen in hematoporphyrin derivative-cysteine,-NADH and-light systems | |
| CA2774893A1 (en) | Antiseptic ointment comprising bentonite intercalated with silver, copper or zinc for external application | |
| CN103945690B (en) | The generation method of silver-ion antibiotic liquid, the generation method of the silver-ion antibiotic liquid generated with this method or silver-ion antibiotic powder, the silver-ion antibiotic powder generated with this method | |
| Bharathi et al. | Synthesis of chitosan and gum arabic functionalized silver nanocomposite for efficient removal of methylene blue and antibacterial activity | |
| RU2190573C2 (en) | Antimicrobial ionizer and method for preparing solution usable for treating and preventing diseases | |
| Skiba et al. | The plasma-chemical formation of polysorbate 80-coated silver nanoparticles and composite materials for water treatment | |
| CN105638731A (en) | Preparation method of antibacterial sepiolite powder | |
| Webb | Factors affecting the viability of air-borne bacteria: IV. The inactivation and reactivation of air-borne Serratia marcescens by ultraviolet and visible light | |
| Al-Ogaidi et al. | Enhancement of antimicrobial activity of silver nanoparticles using lasers | |
| CN113040135A (en) | Nano-silver composite hydrosol disinfectant and preparation method thereof | |
| CN106735308A (en) | A kind of preparation method of food-grade small particle nano silver colloidal sol | |
| JP2008526851A (en) | Silver / water, silver gel, and silver-based compositions and methods for making and using them | |
| JP2005139102A (en) | Platinum nanocolloid-containing cosmetic | |
| CN113182528B (en) | Gold nanocage material capable of photoresponse releasing NO and resisting MRSA biofilm as well as preparation method and application of gold nanocage material | |
| DE2217399A1 (en) | Antimicrobial compsn - contg colloidal heavy metals | |
| Lashkari et al. | Surface plasmon resonance of naked gold nanoparticles for photodynamic inactivation of Escherichia coli | |
| RU2422377C2 (en) | Biocidal concentrate | |
| US2853449A (en) | Slime preventative compositions and methods | |
| CN116173209A (en) | Application of carbon nanodots in the preparation of photocatalytic drugs | |
| US9427411B2 (en) | Oxygenated antimicrobial topical composition |